22/06/2026
Shaping vaccine safety evidence across Europe
DSRU colleagues have contributed to a major VAC4EU study examining thrombosis with thrombocytopaenia syndrome (TTS) — a rare blood clotting condition — following the Oxford-AstraZeneca COVID-19 vaccine. The findings are published in Vaccine.
The UK arm of the study drew on CPRD Aurum, the UK's database of anonymised primary care records. Across the UK, Spain and the Netherlands, the study included more than 5.3 million people who received the AstraZeneca vaccine.
Key findings:
- Possible increased risk of TTS after vaccination, particularly after the first dose
- Higher risk observed in people aged under 60
- Risk window: 1–42 days after vaccination
- Results varied between countries and data sources
This underlines why collaborative, real-world evidence matters in vaccine safety monitoring.
We're proud to contribute to this important European collaboration.
Read the full paper here: https://www.sciencedirect.com/science/article/pii/S0264410X26005323?dgcid=coauthor
https://www.dsru.org/dsrunews/shaping-vaccine-safety-evidence-across-europe/
